Cancer immunology, immunotherapy : CII.
Publisher:
Springer International,. Berlin : Springer Verlag
Frequency: Twelve no. a year
Country: Germany
Language: English
Start Year:1982 -
ISSN:
0340-7004 (Print)
1432-0851 (Electronic)
0340-7004 (Linking)
1432-0851 (Electronic)
0340-7004 (Linking)
Impact Factor
5.8
2022
| NLM ID: | 8605732 |
| (DNLM): | SR0056567(s) |
| (OCoLC): | 09799069 |
| LCCN: | sn 84010370 |
| Classification: | W1 CA679UL |
Novel ocular immunotherapy induces tumor regression in an equine model of ocular surface squamous neoplasia. Ocular surface squamous neoplasia (OSSN) is the major cause of corneal cancer in man and horses worldwide, and the prevalence of OSSN is increasing due to greater UVB exposure globally. Currently, there are no approved treatments for OSSN in either species, and most patients are managed with surgical excision or off-label treatment with locally injected interferon alpha, or topically applied cytotoxic drugs such as mitomycin C. A more broadly effective and readily applied immunotherapy could exert a significant impact on management of OSSN worldwide. We therefore evaluated the effectiveness of...
Comparison of the efficacy of local treatment of equine sarcoids with IL-2 or cisplatin/IL-2. Local interleukin-2 (IL-2) is effective in a number of experimental animal models and in veterinary and human cancer patients without discomforting side effects. The primary goal of this study was to compare the therapeutic effects and side effects of the local intratumoral administration of five or ten low doses of IL-2 with those of a combination of cisplatin and a single high dose of IL-2 in the treatment of equine sarcoids. The therapeutic effect (complete and partial regression) of local cisplatin together with a single high dose of IL-2 was significantly better than the combined effect o...
Equine sarcoid: BCG immunotherapy compared to cryosurgery in a prospective randomised clinical trial. A total of 30 horses with single or multiple sarcoid tumors of the skin were randomly divided into three treatment groups: (i) cryosurgical treatment, (ii) intralesional immunotherapy with a live BCG vaccine, (iii) intralesional immunotherapy with a BCG cell wall preparation. Complete tumour regression was obtained in all 10 cryosurgically treated horses, in 6 of 10 live BCG treated horses, and in 7 of 10 BCG cell wall treated horses. One live BCG and 2 BCG cell wall treated horses showed partial tumour regression of more than 50% of the tumour area. Eleven horses with sarcoid tumours were not...